Literature DB >> 22326558

Protein profiling reveals energy metabolism and cytoskeletal protein alterations in LMNA mutation carriers.

Cinzia Magagnotti1, Angela Bachi, Gianpaolo Zerbini, Elena Fattore, Isabella Fermo, Michela Riba, Stefano C Previtali, Maurizio Ferrari, Annapaola Andolfo, Sara Benedetti.   

Abstract

Nuclear envelope-related muscular dystrophies, in particular those referred to as laminopathies, are relatively novel and unclear diseases, also considering the increasing number of mutations identified so far in genes of the nuclear envelope. As regard LMNA gene, only tentative relations between phenotype, type and localization of the mutations have been established in striated muscle diseases, while laminopathies affecting adipose tissue, peripheral nerves or progerioid syndromes could be linked to specific genetic variants. This study describes the biochemical phenotype of neuromuscular laminopathies in samples derived from LMNA mutant patients. Since it has been reported that nuclear alterations, due to LMNA defects, are present also in fibroblasts from Emery-Dreifuss muscular dystrophy and familial partial lipodystrophy patients, we analyzed 2D-maps of skin fibroblasts of patients carrying 12 different LMNA mutations spread along the entire gene. To recognize distinctive proteins underlying affected biochemical pathways, we compared them with fibroblasts from healthy controls and, more importantly, fibroblasts from patients with non-lamin related neuromuscular disorders. We found less abundance of cytoskeletal/structural proteins, confirming a dominant role for Lamin A/C in structural support of nuclear architecture. Interestingly, we also established significant changes in the expression of proteins involved in cellular energy production and oxidative stress response. To our knowledge, this is the first report where proteomics was applied to characterize ex-vivo cells from LMNA patients, suggesting that this may represent a new approach to better understand the molecular mechanisms of these rare diseases and facilitate the development of novel therapeutic treatments.
© 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22326558     DOI: 10.1016/j.bbadis.2012.01.014

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

1.  Deregulation of focal adhesion formation and cytoskeletal tension due to loss of A-type lamins.

Authors:  Tobias D J Corne; Tom Sieprath; Jonathan Vandenbussche; Danahe Mohammed; Mariska Te Lindert; Kris Gevaert; Sylvain Gabriele; Katarina Wolf; Winnok H De Vos
Journal:  Cell Adh Migr       Date:  2016-11-16       Impact factor: 3.405

2.  Differential Expression of Proteins in an Atypical Presentation of Autoimmune Lymphoproliferative Syndrome.

Authors:  Dulce María Delgadillo; Adriana Ivonne Céspedes-Cruz; Emmanuel Ríos-Castro; María Guadalupe Rodríguez Maldonado; Mariel López-Nogueda; Miguel Márquez-Gutiérrez; Rocío Villalobos-Manzo; Lorena Ramírez-Reyes; Misael Domínguez-Fuentes; José Tapia-Ramírez
Journal:  Int J Mol Sci       Date:  2022-05-11       Impact factor: 6.208

3.  Progeroid syndrome patients with ZMPSTE24 deficiency could benefit when treated with rapamycin and dimethylsulfoxide.

Authors:  Baris Akinci; Shireesha Sankella; Christopher Gilpin; Keiichi Ozono; Abhimanyu Garg; Anil K Agarwal
Journal:  Cold Spring Harb Mol Case Stud       Date:  2017-01

4.  LMNA Mutations G232E and R482L Cause Dysregulation of Skeletal Muscle Differentiation, Bioenergetics, and Metabolic Gene Expression Profile.

Authors:  Elena V Ignatieva; Oksana A Ivanova; Margarita Y Komarova; Natalia V Khromova; Dmitrii E Polev; Anna A Kostareva; Alexey Sergushichev; Renata I Dmitrieva
Journal:  Genes (Basel)       Date:  2020-09-07       Impact factor: 4.096

Review 5.  Oxidative Stress, Inflammation and Connexin Hemichannels in Muscular Dystrophies.

Authors:  Arlek González-Jamett; Walter Vásquez; Gabriela Cifuentes-Riveros; Rafaela Martínez-Pando; Juan C Sáez; Ana M Cárdenas
Journal:  Biomedicines       Date:  2022-02-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.